POST Online Media Lite Edition



 

Cancer Genetics in partnership with AstraZeneca CAMCAR

Staff writer |
Cancer Genetics, Inc. has been selected by AstraZeneca CAMCAR, S.A. to provide biomarker-based diagnostic testing for cancer.




Under the terms of the agreement, CGI will perform complex testing for diagnosis and prognosis of cancer patients in Central America and the Caribbean. CGI will work in close conjunction with AZ-CAMCAR on exploring expansion opportunities into additional geographic territories, further oncology categories, and into select oncology trials.

The relationship is expected to concentrate on multiple cancer categories, with lung cancer being an initial area of focus. According to the Pan American Health Organization ("PAHO"), lung cancer is the third most common cancer and the leading cause of cancer deaths in the Americas, with more than 300,000 new cases and nearly 250,000 deaths each year. PAHO expects the number of new cases and deaths from lung cancer to double in Latin America by 2030.


What to read next

Cancer Genetics completes $14 million Response Genetics acquisition
Cancer Genetics to acquire Response Genetics
AstraZeneca, Merck in collaboration on cancer drug, will receive up to $8.5 billion